Log in to save to my catalogue

Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profilin...

Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profilin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10067384

Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Comprehensive cancer genome profiling (CGP) has been nationally reimbursed in Japan since June 2019. Less than 10% of the patients have been reported to undergo recommended treatment. Todai OncoPanel (TOP) is a dual DNA–RNA panel as well as a paired tumor–normal matched test. Two hundred patients underwent TOP as part of Advanced Medical Care B wit...

Alternative Titles

Full title

Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10067384

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10067384

Other Identifiers

ISSN

1347-9032

E-ISSN

1349-7006

DOI

10.1111/cas.15717

How to access this item